Press Release
« Back
TG Therapeutics, Inc. Announces Clinical Data Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Milan, Italy
May 22, 2014
The following abstracts have been accepted for presentation:
-
Title: Ublituximab (TG-1101), a novel glycoengineered anti-CD20 MAB, in combination with ibrutinib in patients with CLL and MCL; results of an ongoing phase II trial
- Abstract Number: P880
-
Date and Time:
Saturday June 14, 2014 ,5:45 -7:00pm CEST - Poster Display: NW - Level 0
-
Lead Author:
Jeff P. Sharman , MD
-
Title: Ublituximab (TG-1101), a novel anti-CD20 monoclonal for rituximab relapsed/refractory B-Cell malignancies
- Abstract Number: P444
-
Date and Time:
Friday June 13, 2014 ,5:45pm -7:00pm CEST - Poster Display: NW - Level 0
-
Lead Author:
Owen A. O'Connor , MD, PhD
-
Title: TGR-1202, a novel once daily PI3K delta inhibitor, demonstrates promising clinical activity with a favorable safety profile in patients with relapsed or refractory hematologic malignancies
- Abstract Number: P250
-
Date and Time:
Friday June 13, 2014 ,5:45pm -7:00pm CEST - Poster Display: NW- Level 0
-
Lead Author:
Howard A. Burris , MD
In addition to the above, at the 50th Annual Meeting of
Finally, a clinical update on the combination study of TG-1101 and TGR-1202 will be presented at the 2014
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not produce
satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director - Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media